GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
The online model returned to the hospital three days later after experiencing chest tightness, a rash, blurred vision ... She hopes to get her vision back, so she can go back to work.